breast cancer
Conditions
Interventions
receiving HER2 targeted drugs trastuzumab + pertuzumab:None
receiving HER2 targeted drugs trastuzumab:none
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged 18 or older and less than or equal to 70 years old; 2. All patients were diagnosed as HER-2 positive breast cancer by histopathology; 3. The functional level of organs is basically normal: bone marrow function, liver and kidney function, heart; 4. In the late stage, they have not received chemotherapy or biotherapy for metastatic disease; 5. The Eastern Cooperative Oncology Group (ECOG) performance status is 0 or =1; 6. Left ventricular ejection fraction (LVEF) is at least 50%; 7. The first-line treatment for advanced cancer is based on paclitaxel, with or without targeted therapy.
Exclusion criteria
Exclusion criteria: 1. Those who have received any form of traditional Chinese medicine treatment in the first-line treatment in the late stage; 2. Accepting other anti-tumor treatments for other tumors at the same time; 3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer, central nervous system metastasis; 4. Having had other malignant tumors in the past 5 years, except for cured cervical carcinoma in situ; 5. Patients with severe dysfunction of important organs such as the heart, liver, and kidneys; 6. Have any previous heart disease, including: (1) arrhythmia requiring medication or having clinical significance; (2) myocardial infarction; (3) heart failure; (4) any other heart disease judged by the investigator as not suitable for participating in this trial; 7. Female patients in pregnancy and lactation period; 8. There are infectious diseases, such as chronic pneumonia in the acute phase, tuberculosis, hepatitis; Existence of autoimmune diseases, such as lupus erythematosus, chronic glomerulonephritis, etc; 9. Patients with acute and chronic injuries, blood system diseases, and end-stage renal disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between neutrophil/lymphocyte ratio and progression free survival (PFS) of breast cancer; | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation between platelet/lymphocyte ratio and progression free survival (PFS) of breast cancer;Correlation between systemic immune inflammation index and disease-free progression of breast cancer (PFS); | — |
Countries
China
Contacts
Public ContactZhi Xiao
Xiangya Hospital, Central South University
Outcome results
None listed